pharmaceuticals

pharmaceuticals Articles

As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the new Trump...
Major Dow Jones Industrial Average companies in the health care sector saw a relatively strong 2016, with most posting a solid gain on the year.
A few biotech and pharma companies were on the move Wednesday, some making absolutely massive gains on the day, giving more credence to the Trump rally and positive sentiment for the health care...
Braeburn Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
To kick off the New Year, Clovis Oncology a few other biotech companies made massive runs on this first day of trading in 2017.
Inotek Pharmaceuticals saw its shares get more than halved early on Tuesday after the company provided an update on its late-stage glaucoma trial.
24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
The SEC has announced that Teva Pharmaceutical Industries has agreed to pay over $519 million to settle charges that it violated the Foreign Corrupt Practices Act by paying bribes to foreign...
Shares of Amphastar Pharmaceuticals fell on Tuesday after the company announced that a subsidiary had received a Complete Response Letter from the FDA.
Visterra has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Shares of Merrimack Pharmaceuticals dropped on Wednesday after the company reported that it would stop a mid-stage cancer study.
Inovio Pharmaceuticals shares saw a handy gain on Wednesday after the company reported positive results from its early-stage Zika trial.
Conatus Pharmaceuticals saw its shares more than double early on Tuesday after the company reported an exclusive collaboration and license agreement for its cirrhosis treatment.
Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares hit a new 52-week high after the company reported a key U.S. Food and Drug Administration (FDA) approval. Essentially, the FDA approved...